Cargando…

Cytochrome b(5) plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine

ABSTRACT: Ellipticine is an anticancer agent that forms covalent DNA adducts after enzymatic activation by cytochrome P450 (CYP) enzymes, mainly by CYP3A4. This process is one of the most important ellipticine DNA-damaging mechanisms for its antitumor action. Here, we investigated the efficiencies o...

Descripción completa

Detalles Bibliográficos
Autores principales: Stiborová, Marie, Indra, Radek, Frei, Eva, Kopečková, Kateřina, Schmeiser, Heinz H., Eckschlager, Tomáš, Adam, Vojtěch, Heger, Zbyněk, Arlt, Volker M., Martínek, Václav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5653753/
https://www.ncbi.nlm.nih.gov/pubmed/29104319
http://dx.doi.org/10.1007/s00706-017-1986-9
_version_ 1783273268057210880
author Stiborová, Marie
Indra, Radek
Frei, Eva
Kopečková, Kateřina
Schmeiser, Heinz H.
Eckschlager, Tomáš
Adam, Vojtěch
Heger, Zbyněk
Arlt, Volker M.
Martínek, Václav
author_facet Stiborová, Marie
Indra, Radek
Frei, Eva
Kopečková, Kateřina
Schmeiser, Heinz H.
Eckschlager, Tomáš
Adam, Vojtěch
Heger, Zbyněk
Arlt, Volker M.
Martínek, Václav
author_sort Stiborová, Marie
collection PubMed
description ABSTRACT: Ellipticine is an anticancer agent that forms covalent DNA adducts after enzymatic activation by cytochrome P450 (CYP) enzymes, mainly by CYP3A4. This process is one of the most important ellipticine DNA-damaging mechanisms for its antitumor action. Here, we investigated the efficiencies of human hepatic microsomes and human recombinant CYP3A4 expressed with its reductase, NADPH:CYP oxidoreductase (POR), NADH:cytochrome b (5) reductase and/or cytochrome b (5) in Supersomes™ to oxidize this drug. We also evaluated the effectiveness of coenzymes of two of the microsomal reductases, NADPH as a coenzyme of POR, and NADH as a coenzyme of NADH:cytochrome b (5) reductase, to mediate ellipticine oxidation in these enzyme systems. Using HPLC analysis we detected up to five ellipticine metabolites, which were formed by human hepatic microsomes and human CYP3A4 in the presence of NADPH or NADH. Among ellipticine metabolites, 9-hydroxy-, 12-hydroxy-, and 13-hydroxyellipticine were formed by hepatic microsomes as the major metabolites, while 7-hydroxyellipticine and the ellipticine N (2)-oxide were the minor ones. Human CYP3A4 in Supersomes™ generated only three metabolic products, 9-hydroxy-, 12-hydroxy-, and 13-hydroxyellipticine. Using the (32)P-postlabeling method two ellipticine-derived DNA adducts were generated by microsomes and the CYP3A4-Supersome system, both in the presence of NADPH and NADH. These adducts were derived from the reaction of 13-hydroxy- and 12-hydroxyellipticine with deoxyguanosine in DNA. In the presence of NADPH or NADH, cytochrome b (5) stimulated the CYP3A4-mediated oxidation of ellipticine, but the stimulation effect differed for individual ellipticine metabolites. This heme protein also stimulated the formation of both ellipticine-DNA adducts. The results demonstrate that cytochrome b (5) plays a dual role in the CYP3A4-catalyzed oxidation of ellipticine: (1) cytochrome b (5) mediates CYP3A4 catalytic activities by donating the first and second electron to this enzyme in its catalytic cycle, indicating that NADH:cytochrome b (5) reductase can substitute NADPH-dependent POR in this enzymatic reaction and (2) cytochrome b (5) can act as an allosteric modifier of the CYP3A4 oxygenase. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-5653753
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-56537532017-11-01 Cytochrome b(5) plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine Stiborová, Marie Indra, Radek Frei, Eva Kopečková, Kateřina Schmeiser, Heinz H. Eckschlager, Tomáš Adam, Vojtěch Heger, Zbyněk Arlt, Volker M. Martínek, Václav Monatsh Chem Original Paper ABSTRACT: Ellipticine is an anticancer agent that forms covalent DNA adducts after enzymatic activation by cytochrome P450 (CYP) enzymes, mainly by CYP3A4. This process is one of the most important ellipticine DNA-damaging mechanisms for its antitumor action. Here, we investigated the efficiencies of human hepatic microsomes and human recombinant CYP3A4 expressed with its reductase, NADPH:CYP oxidoreductase (POR), NADH:cytochrome b (5) reductase and/or cytochrome b (5) in Supersomes™ to oxidize this drug. We also evaluated the effectiveness of coenzymes of two of the microsomal reductases, NADPH as a coenzyme of POR, and NADH as a coenzyme of NADH:cytochrome b (5) reductase, to mediate ellipticine oxidation in these enzyme systems. Using HPLC analysis we detected up to five ellipticine metabolites, which were formed by human hepatic microsomes and human CYP3A4 in the presence of NADPH or NADH. Among ellipticine metabolites, 9-hydroxy-, 12-hydroxy-, and 13-hydroxyellipticine were formed by hepatic microsomes as the major metabolites, while 7-hydroxyellipticine and the ellipticine N (2)-oxide were the minor ones. Human CYP3A4 in Supersomes™ generated only three metabolic products, 9-hydroxy-, 12-hydroxy-, and 13-hydroxyellipticine. Using the (32)P-postlabeling method two ellipticine-derived DNA adducts were generated by microsomes and the CYP3A4-Supersome system, both in the presence of NADPH and NADH. These adducts were derived from the reaction of 13-hydroxy- and 12-hydroxyellipticine with deoxyguanosine in DNA. In the presence of NADPH or NADH, cytochrome b (5) stimulated the CYP3A4-mediated oxidation of ellipticine, but the stimulation effect differed for individual ellipticine metabolites. This heme protein also stimulated the formation of both ellipticine-DNA adducts. The results demonstrate that cytochrome b (5) plays a dual role in the CYP3A4-catalyzed oxidation of ellipticine: (1) cytochrome b (5) mediates CYP3A4 catalytic activities by donating the first and second electron to this enzyme in its catalytic cycle, indicating that NADH:cytochrome b (5) reductase can substitute NADPH-dependent POR in this enzymatic reaction and (2) cytochrome b (5) can act as an allosteric modifier of the CYP3A4 oxygenase. GRAPHICAL ABSTRACT: [Image: see text] Springer Vienna 2017-07-04 2017 /pmc/articles/PMC5653753/ /pubmed/29104319 http://dx.doi.org/10.1007/s00706-017-1986-9 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Paper
Stiborová, Marie
Indra, Radek
Frei, Eva
Kopečková, Kateřina
Schmeiser, Heinz H.
Eckschlager, Tomáš
Adam, Vojtěch
Heger, Zbyněk
Arlt, Volker M.
Martínek, Václav
Cytochrome b(5) plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine
title Cytochrome b(5) plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine
title_full Cytochrome b(5) plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine
title_fullStr Cytochrome b(5) plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine
title_full_unstemmed Cytochrome b(5) plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine
title_short Cytochrome b(5) plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine
title_sort cytochrome b(5) plays a dual role in the reaction cycle of cytochrome p450 3a4 during oxidation of the anticancer drug ellipticine
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5653753/
https://www.ncbi.nlm.nih.gov/pubmed/29104319
http://dx.doi.org/10.1007/s00706-017-1986-9
work_keys_str_mv AT stiborovamarie cytochromeb5playsadualroleinthereactioncycleofcytochromep4503a4duringoxidationoftheanticancerdrugellipticine
AT indraradek cytochromeb5playsadualroleinthereactioncycleofcytochromep4503a4duringoxidationoftheanticancerdrugellipticine
AT freieva cytochromeb5playsadualroleinthereactioncycleofcytochromep4503a4duringoxidationoftheanticancerdrugellipticine
AT kopeckovakaterina cytochromeb5playsadualroleinthereactioncycleofcytochromep4503a4duringoxidationoftheanticancerdrugellipticine
AT schmeiserheinzh cytochromeb5playsadualroleinthereactioncycleofcytochromep4503a4duringoxidationoftheanticancerdrugellipticine
AT eckschlagertomas cytochromeb5playsadualroleinthereactioncycleofcytochromep4503a4duringoxidationoftheanticancerdrugellipticine
AT adamvojtech cytochromeb5playsadualroleinthereactioncycleofcytochromep4503a4duringoxidationoftheanticancerdrugellipticine
AT hegerzbynek cytochromeb5playsadualroleinthereactioncycleofcytochromep4503a4duringoxidationoftheanticancerdrugellipticine
AT arltvolkerm cytochromeb5playsadualroleinthereactioncycleofcytochromep4503a4duringoxidationoftheanticancerdrugellipticine
AT martinekvaclav cytochromeb5playsadualroleinthereactioncycleofcytochromep4503a4duringoxidationoftheanticancerdrugellipticine